Efficacy assessment of PEV2 phage on Galleria mellonella larvae infected with a Pseudomonas aeruginosa dog otitis isolate

Antoine, Céline; Laforêt, Fanny; Blasdel, Bob; Glonti, Tea; Kutter, Elizabeth; Pirnay, Jean‐Paul; Mainil, Jacques; Delcenserie, Véronique; Thiry, Damien

doi:10.1016/j.rvsc.2021.04.010

Cited by 17 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most important attributes phage therapy can provide is the ability to circumvent traditional mechanisms of antibiotic resistance seen in MDR/XDR- P. aeruginosa . This principle was demonstrated in a study examining the efficacy of phage ØA392 against an imipenem-resistant P. aeruginosa isolate in a mouse model where phage demonstrated microbiological eradication [ 128 ]. Against P. aeruginosa isolates obtained from patients with CF, phage produces enzymes to break up biofilms and alginate associated with mucoid P. aeruginosa strains [ 129 ].…”

Section: Bacteriophage Therapymentioning

confidence: 99%

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa

et al. 2022

View full text Add to dashboard Cite

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa isolates are frequent causes of serious nosocomial infections that may compromise the selection of antimicrobial therapy. The goal of this review is to summarize recent epidemiologic, microbiologic, and clinical data pertinent to the therapeutic management of patients with infections caused by MDR/XDR-P. aeruginosa. Historically, conventional antipseudomonal b-lactam antibiotics have been used for the empiric treatment of MDR/XDR-P. aeruginosa. Owing to the remarkable capacity of

show abstract

Section: Bacteriophage Therapymentioning

confidence: 99%

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa

et al. 2022

View full text Add to dashboard Cite

show abstract

“…An important advantage of P. aeruginosa phage therapy is the ability to evade traditional mechanisms of antimicrobial resistance, as commonly seen in MDR/XDR/PDR Pseudomonas infections. For example, one study demonstrated the efficacy of phage ØA392 against imipenem-resistant P. aeruginosa bacteremia in an experimental mouse model [10], where the single-dose, intraperitoneal administration of phage ØA392 was sufficient to rescue 100% of the animals. Inherited resistance is not the only reason antibiotic therapy would fail.…”

Section: Benefits Of Pseudomonas Phage Therapymentioning

confidence: 99%

“…Phage therapy is primarily practiced today in parts of Eastern and Western Europe, with a research facility dedicated to phage therapeutics, the Eliava Institute, located in Tbilisi, Georgia [9]. The success of phage therapy for the treatment of P. aeruginosa infections in animals and humans has been validated in several case reports, as well as in small clinical and preclinical trials [10][11][12][13][14][15][16][17]. However, there remains much to be discovered in terms of the pharmacokinetics and pharmacodynamics (PK/PD) of phage therapy, specifically in the context of clinical applications and their role as combination therapy with antibiotics.…”

Section: Introductionmentioning

confidence: 99%

Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections

et al. 2021

View full text Add to dashboard Cite

Pseudomonas aeruginosa is one of the most common causes of healthcare-associated diseases and is among the top three priority pathogens listed by the World Health Organization (WHO). This Gram-negative pathogen is especially difficult to eradicate because it displays high intrinsic and acquired resistance to many antibiotics. In addition, growing concerns regarding the scarcity of antibiotics against multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa infections necessitate alternative therapies. Bacteriophages, or phages, are viruses that target and infect bacterial cells, and they represent a promising candidate for combatting MDR infections. The aim of this review was to highlight the clinical pharmacology considerations of phage therapy, such as pharmacokinetics, formulation, and dosing, while addressing several challenges associated with phage therapeutics for MDR P. aeruginosa infections. Further studies assessing phage pharmacokinetics and pharmacodynamics will help to guide interested clinicians and phage researchers towards greater success with phage therapy for MDR P. aeruginosa infections.

show abstract

“…There is a need to improve the current workflow, from phage discovery to the application of phages, which includes investigating the efficacy of a phage in a simple animal model ( 17 , 18 ). Many studies have reported the use of wax worms ( Galleria mellonella ) as a model to study the efficacy of bacteriophages ( 15 , 19 – 22 ). However, it requires a skillful operator to inject bacteria and/or phages into individual larvae, which sometimes could result in large variations between batches and thus lead to nonreproducible observations.…”

Section: Introductionmentioning

confidence: 99%